OGEN
HEALTHCAREOragenics Inc
$0.62-0.02 (-2.97%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving OGEN Today?
No stock-specific AI insight has been generated for OGEN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.50$9.60
$0.62
Fundamentals
Market Cap$3M
P/E Ratio—
EPS$-4.56
Dividend Yield—
Dividend / Share—
ROE-2.4%
Profit Margin—
Debt / Equity—
Trading
Volume27K
Avg Volume (10D)—
Shares Outstanding4.3M
OGEN News
20 articles- Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic InflammationYahoo Finance·May 7, 2026
- Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.Yahoo Finance·May 5, 2026
- Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain InjuryYahoo Finance·Apr 20, 2026
- Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain InjuryYahoo Finance·Apr 13, 2026
- Oragenics, Inc. Receives Audit Opinion with Going Concern ExplanationYahoo Finance·Mar 25, 2026
- ORAGENICS FILES ANNUAL REPORT ON FORM 10-KYahoo Finance·Mar 17, 2026
- ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATIONYahoo Finance·Mar 12, 2026
- ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTIONYahoo Finance·Mar 11, 2026
- Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in AustraliaYahoo Finance·Mar 10, 2026
- Oragenics previews targeted milestones for 2026Yahoo Finance·Feb 10, 2026
- Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury TherapyYahoo Finance·Feb 9, 2026
- Oragenics partners with Duck Flats Pharma to support FDA IND trial designYahoo Finance·Feb 4, 2026
- Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion ProgramYahoo Finance·Feb 3, 2026
- Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient CareYahoo Finance·Feb 2, 2026
- Oragenics to Present at the 2026 Sequire Investor Summit in Puerto RicoYahoo Finance·Jan 14, 2026
- Oragenics Q3 2025 Shareholder UpdateYahoo Finance·Nov 12, 2025
- Oragenics: Q3 Earnings SnapshotYahoo Finance·Nov 7, 2025
- Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity DeficiencyYahoo Finance·Oct 21, 2025
- Oragenics partners Receptor.AI for brain health candidate portfolioPharmaceutical-technology·Oct 8, 2025
- Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline DevelopmentYahoo Finance·Oct 7, 2025
All 20 articles loaded
Price Data
Open$0.65
Previous Close$0.64
Day High$0.65
Day Low$0.62
52 Week High$9.60
52 Week Low$0.50
52-Week Range
$0.50$9.60
$0.62
Fundamentals
Market Cap$3M
P/E Ratio—
EPS$-4.56
Dividend Yield—
Dividend / Share—
ROE-2.4%
Profit Margin—
Debt / Equity—
Trading
Volume27K
Avg Volume (10D)—
Shares Outstanding4.3M
About Oragenics Inc
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company is headquartered in Tampa, Florida.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—